Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
Nintedanib* has been investigated in lung cancer as part of the LUME-Lung clinical trial programme. Within this section you will find an overview of the main trials within this programme as well as links to pages for further information.
Nintedanib clinical trials in NSCLC
The approval of nintedanib for the treatment of adult patients with advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy is based on the Phase III LUME-Lung 1 trial.1
The following table shows the clinical trials of nintedanib in NSCLC; you can find links to further information on this site and published papers.
Ongoing clinical trials in NSCLC
ADRs, adverse drug reactions; DLT, dose-limiting toxicity; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; SAEs, serious adverse events.
Reck M, et al. Lancet Oncol 2014;15(2):143-55.
ClinicalTrials.gov. NCT02668393. https://clinicaltrials.gov/ct2/show/study/NCT02668393 (Accessed: January 2019).
ClinicalTrials.gov. NCT03017885. https://clinicaltrials.gov/ct2/show/study/NCT03017885 (Accessed: January 2019).
Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT02671422 (Accessed: February 2019).
Reck M, et al. Poster presented at ESMO 2017 (Poster 1382TiP).
*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
Page last updated: March 2019
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue